RxDoctor Payments Data

Thomas Fischer, MD

Family Medicine · Lincoln, NENPI 1215310610

Payments from drug & device makers

$371in general payments, 2019–2025

Across 14 payments — averaging $26.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$143
  • AbbVie$86
  • Astellas Pharma US Inc$35
  • Novo Nordisk$29
  • Amarin Pharma, Inc.$20
  • Johnson & Johnson$18
  • plus $40 from 3 others

What the payments were for

  • Food & beverage$371100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$371 in reported general payments places this provider in the 45th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$147,616
Medicare patients
382
Services billed
4,934

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban73$100,792
FarxigaDapagliflozin Propanediol48$73,206
EliquisApixaban69$66,663
TrulicityDulaglutide42$53,400
JardianceEmpagliflozin33$45,267
MounjaroTirzepatide23$34,490
OzempicSemaglutide23$25,834
UbrelvyUbrogepant12$12,608
SymbicortBudesonide/Formoterol Fumarate19$9,079
MyrbetriqMirabegron12$9,036
ShingrixVaricella-Zoster Ge/As01b/Pf39$8,555
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$6,859
Spiriva HandihalerTiotropium Bromide13$6,699
SynthroidLevothyroxine Sodium56$4,806
Rosuvastatin Calcium229$3,946

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$18$100,79273 claims
AstraZenecaFarxiga, Symbicort$13$82,28567 claims
Novo NordiskOzempic$29$25,83423 claims
AbbVieUbrelvy, Synthroid$86$17,41568 claims
GSKShingrix, Arnuity Ellipta$13$11,72550 claims
Astellas Pharma US IncMyrbetriq$35$9,03612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →